First report of icatibant treatment in a pregnant patient with hereditary angioedema

H. Farkas, Kinga Viktória Kőhalmi, Nóra Veszeli, Ferenc Tóth, L. Varga

Research output: Article

9 Citations (Scopus)

Abstract

Hereditary angioedema resulting from C1-inhibitor deficiency (C1-INH-HAE) is a rare, autosomal dominant disorder, characterized by recurrent attacks of edema formation. The management of pregnant patients with C1-INH-HAE is often a challenge for the physician. There is limited experience with novel therapies. Plasma-derived nanofiltered C1-INH (pnfC1-INH) is the only recommended therapeutic option during pregnancy. In our 26-year-old female patient with type II C1-INH-HAE, pregnancy was confirmed in the sixth week of gestation. During this period, the patient received the bradykinin B2-receptor antagonist, icatibant, on five occasions, as acute treatment. She experienced 119 attacks, for which she received 108 vials of pnfC1-INH during her pregnancy. The patient gave birth to a healthy baby. No side effects were detected with either treatment. No reports have been published to date on multiple dosing with icatibant during the first trimester of pregnancy. This therapy proved effective and free of maternal or fetal adverse effects.

Original languageEnglish
Pages (from-to)1026-1028
Number of pages3
JournalJournal of Obstetrics and Gynaecology Research
Volume42
Issue number8
DOIs
Publication statusPublished - aug. 1 2016

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'First report of icatibant treatment in a pregnant patient with hereditary angioedema'. Together they form a unique fingerprint.

  • Cite this